• Event Type: Q1 FY27 Earnings Conference Call held on Thursday, August 6, 2026, to discuss financial results for the quarter ended June 30, 2026.
  • Date and Time: The call was held on August 6, 2026. No specific time or time zone was mentioned in the transcript.
  • Purpose: To discuss the company's financial performance, provide a strategic update on the TruBridge acquisition, and outline the medium-term outlook.
  • Management Participants:
  • Mr. Sachin Gupta – Founder and Global Chief Executive Officer
  • Ms. Nithya Balasubramanian – Whole-Time Director & Chief Financial Officer
  • Mr. Saransh Mundra – VP, Investor Relations
  • Moderator: Ms. Seema Nayak from ICICI Securities
  • Availability of Materials: The transcript of the call was filed with the exchanges and is available on the company's website at: https://ikshealth.com/ir/2027/q1/transcript-q1.pdf
  • UPSI Statement: The company included a standard disclaimer during the call that forward-looking statements involve estimations and uncertainties, and they do not take responsibility to update such statements.
  • Financial Period Discussed: Q1 FY27 (quarter ended June 30, 2026).
  • Financial Highlights:
  • Revenue: INR893 crores, up 21% YoY (12% constant currency growth)
  • EBITDA: INR294 crores (33% margin); adjusted for one-time TruBridge acquisition costs of ~INR20 crores, EBITDA would be INR314 crores (~35% margin)
  • PAT: INR193 crores, up 28% YoY
  • Headcount: 12,889 employees (pre-TruBridge), up 4.2% YoY
  • EPS: grew 30% YoY
  • Return on Equity: 26%
  • Tax Rate: 22.4% for legacy IKS business
  • Free Cash Flow Yield: 90% (adjusted for one-time costs)
  • Strategic Updates:
  • TruBridge acquisition closed on July 10, 2026. Pro forma revenue base reset to $300M annually (from earlier $340M expectation) while maintaining $68M EBITDA. Revenue adjustment due to conservative revenue recognition ($2-3M/quarter), elimination of unprofitable services ($8M/quarter), and anticipated customer discounts ($2-3M/quarter).
  • Five renewed strategic pillars: 1) Integrated system of action/record for rural market, 2) Extending AI workflows to traditional market, 3) Stratified go-to-market strategies, 4) Margin expansion to early-to-mid 30% EBITDA, 5) Cultural integration.
  • AI Strategy: Building proprietary Small Language Models (SLMs) using TruBridge's 5M+ patient dataset, developing explainable AI through knowledge graphs (ARAI acquisition), and implementing task-specific autonomy based on deterministic vs. non-deterministic outcomes.
  • Patent approved for AAW (Awareness, Ability, Willingness) algorithm for patient behavior prediction.
  • Client Wins:
  • Large California health system (Epic implementation partnership)
  • National musculoskeletal leader (RCM relationship)
  • Advocate Health Care (expansion in revenue cycle and coding)
  • StrideCare (vascular and vein surgery organization)
  • Guidance/Outlook:
  • Reiterated True North goal of achieving INR3,000 crores EBITDA by FY30
  • Expect to achieve this with minimal dilution (only ESOPs) and return to pre-TruBridge net debt levels
  • Legacy IKS business aspiration: >12% constant currency growth
  • TruBridge growth outlook to be determined after 2-3 quarters of integration

Additional Notes Section

  • The document is a regulatory filing submitted to BSE and NSE containing the earnings call transcript.
  • The transcript was edited for readability but contains no attachments beyond the web link provided.
  • Financial data was extensively disclosed in the transcript, including revenue, EBITDA, PAT, headcount, and various operational metrics.
  • The company confirmed the TruBridge acquisition was EPS accretive despite revenue rationalization.